Decitabine Plus a JAK-Inhibitor
A Phase 2 Trial Investigating Decitabine in Combination With a JAK-Inhibitor as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated/Blast Phase Myeloproliferative Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Fred Hutchinson Cancer Research Center
- Tags
- JAK2 Inhibitor, Hypomethylating Agents (HMA), JAK1 Inhibitor
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1651
- NCT Identifier
- NCT04282187
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.